Product Information
MK-5204 is a novel antifungal agent that has been shown to have broad-spectrum activity in vitro and in vivo against various human fungal pathogens, including Aspergillus fumigatus. The compound is a carboxamide derivative with an isopropyl group at the C2 position and a triazole at the C3 position. It has been shown to be orally active against murine Candida albicans infection. The structural modifications are designed to increase solubility, reduce toxicity, and improve pharmacokinetics. MK-5204 has completed the first phase of clinical development and is currently undergoing optimization for oral administration.
MK-5204 is being developed by Merck Research Laboratories.
Chemical properties
Technical inquiry about: 3D-BM178545 MK-5204
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
